Targeting drug-resistant prostate cancer with dual PI3K/mTOR inhibition

Current Medicinal Chemistry

Volumn 21, Issue 26, 2014, Pages 3048-3056

  Tang, K D ^a   Ling, Ming Tat ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Drug resistant; MTOR; PI3K; Prostate cancer

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; DACTOLISIB; FISETIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PROTEIN KINASE B; UNCLASSIFIED DRUG; XL 735; XL 765; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; TARGET OF RAPAMYCIN KINASE;

CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); ENZYME INHIBITION; GENE AMPLIFICATION; GENE INACTIVATION; GENE LOSS; GENE MUTATION; HUMAN; METASTASIS; MOLECULAR MECHANICS; PROSTATE CANCER; PTEN GENE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR SUPPRESSOR GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; MALE; METABOLISM; PROSTATIC NEOPLASMS;

ANIMALS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84906091340     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140414100127     Document Type: Review

References (87)

1. Taylor, R.A.; Toivanen, R.; Risbridger, G.P. Stem cells in prostate cancer: treating the root of the problem. Endocr.-Relat. Cancer, 2010, 17(4), R273-R285.
2. de Wit, R. Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone-finally an effective chemotherapy. Eur. J. Cancer, 2005, 41(4), 502-507.
3. Dobbin, Z.C.; Landen, C.N. The Importance of the PI3K/AKT/MTOR Pathway in the Progression of Ovarian Cancer. Int. J. Mol. Sci., 2013, 14(4), 8213-8227.
4. Serra, V.; Markman, B.; Scaltriti, M.; Eichhorn, P.J.; Valero, V.; Guzman, M.; Botero, M.L.; Llonch, E.; Atzori, F.; Di Cosimo, S.; Maira, M.; Garcia-Echeverria, C.; Parra, J.L.; Arribas, J.; Baselga, J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res., 2008, 68(19), 8022-8030.
5. Segerstrom, L.; Baryawno, N.; Sveinbjornsson, B.; Wickstrom, M.; Elfman, L.; Kogner, P.; Johnsen, J.I. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo. Int. J. Cancer, 2011, 129(12), 2958-2965.
6. Owonikoko, T.K.; Khuri, F.R. Targeting the PI3K/AKT/mTOR Pathway. Am. Soc. Clin. Oncol. Educ. Book, 2013, 395-401.
7. Courtney, K.D.; Corcoran, R.B.; Engelman, J.A. The PI3K pathway as drug target in human cancer. Int. J. Clin. Oncol., 2010, 28(6), 1075-1083.
8. Burke, J.E.; Williams, R.L. Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS). Adv. Biol. Regul., 2013, 53(1), 97-110.
9. Cuevas, B.D.; Lu, Y.; Mao, M.; Zhang, J.; LaPushin, R.; Siminovitch, K.; Mills, G.B. Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J. Biol. Chem., 2001, 276(29), 27455-27461.
10. Liu, P.; Cheng, H.; Roberts, T.M.; Zhao, J.J., Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov., 2009, 8(8), 627-644.
11. Morgan, T.M.; Koreckij, T.D.; Corey, E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr. Cancer Drug Targets, 2009, 9(2), 237-249.
12. Courtney, K.D.; Corcoran, R.B.; Engelman, J.A. The PI3K pathway as drug target in human cancer. Int. J. Clin. Oncol., 2010, 28(6), 1075-1083.
13. Utermark, T.; Rao, T.; Cheng, H.; Wang, Q.; Lee, S.H.; Wang, Z.C.; Iglehart, J.D.; Roberts, T.M.; Muller, W.J.; Zhao, J.J. The p110alpha and p110beta isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Devel., 2012, 26(14), 1573-1586.
14. Hennessy, B.T.; Smith, D.L.; Ram, P.T.; Lu, Y.; Mills, G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov., 2005, 4(12), 988-1004.
15. Katso, R.; Okkenhaug, K.; Ahmadi, K.; White, S.; Timms, J.; Waterfield, M.D. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Ann. Rev. Cell Devel. Biol., 2001, 17, 615-675.
16. Engelman, J.A.; Luo, J.; Cantley, L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet., 2006, 7(8), 606-619.
17. Oudit, G.Y.; Sun, H.; Kerfant, B.G.; Crackower, M.A.; Penninger, J.M.; Backx, P.H. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J. Mol. Cell. Cardiol., 2004, 37(2), 449-471.
18. Kok, K.; Geering, B.; Vanhaesebroeck, B. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem. Sci., 2009, 34(3), 115-127.
19. Martini, M.; Ciraolo, E.; Gulluni, F.; Hirsch, E. Targeting PI3K in Cancer: Any Good News? Front. Oncol., 2013, 3, 108.
20. Backer, J.M. The regulation and function of Class III PI3Ks: novel roles for Vps34. Biochem. J., 2008, 410(1), 1-17.
21. Bhatt, A.P.; Bhende, P.M.; Sin, S.H.; Roy, D.; Dittmer, D.P.; Damania, B. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood, 2010, 115(22), 4455-4463.
22. Krohn, A.; Diedler, T.; Burkhardt, L.; Mayer, P.S.; De Silva, C.; Meyer-Kornblum, M.; Kotschau, D.; Tennstedt, P.; Huang, J.; Gerhauser, C.; Mader, M.; Kurtz, S.; Sirma, H.; Saad, F.; Steuber, T.; Graefen, M.; Plass, C.; Sauter, G.; Simon, R.; Minner, S.; Schlomm, T. Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer. Am. J. Pathol., 2012, 181(2), 401-412.
23. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S.M.; Riggins, G.J.; Willson, J.K.; Markowitz, S.; Kinzler, K.W.; Vogelstein, B.; Velculescu, V.E. High frequency of mutations of the PIK3CA gene in human cancers. Science, 2004, 304(5670), 554.
24. Duronio, V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem. J., 2008, 415(3), 333-344.
25. Cully, M.; You, H.; Levine, A.J.; Mak, T.W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer, 2006, 6(3), 184-192.
26. Sengupta, S.; Peterson, T.R.; Sabatini, D.M. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol. Cell., 2010, 40(2), 310-322.
27. Fiano, V.; Ghimenti, C.; Imarisio, S.; Silengo, L.; Schiffer, D. PAkt, cyclin D1 and p27/Kip.1 in glioblastomas with and without EGFR amplification and PTEN mutation. Anticancer Res., 2004, 24(5A), 2643-2647.
28. Lang, C.H.; Frost, R.A. Endotoxin disrupts the leucine-signaling pathway involving phosphorylation of mTOR, 4E-BP1, and S6K1 in skeletal muscle. J. Cell. Physiol., 2005, 203(1), 144-155.
29. Fumarola, C.; La Monica, S.; Alfieri, R.R.; Borra, E.; Guidotti, G.G. Cell size reduction induced by inhibition of the mTOR/S6Ksignaling pathway protects Jurkat cells from apoptosis. Cell Death Differ., 2005, 12(10), 1344-1357.
30. Edwards, E.; Geng, L.; Tan, J.; Onishko, H.; Donnelly, E.; Hallahan, D.E. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res., 2002, 62(16), 4671-4677.
31. Woo, S.Y.; Kim, D.H.; Jun, C.B.; Kim, Y.M.; Haar, E.V.; Lee, S.I.; Hegg, J.W.; Bandhakavi, S.; Griffin, T.J. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. J. Biol. Chem., 2007, 282(35), 25604-25612.
32. Thedieck, K.; Polak, P.; Kim, M.L.; Molle, K.D.; Cohen, A.; Jeno, P.; Arrieumerlou, C.; Hall, M.N. PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PloS One, 2007, 2(11), e1217.
33. Martelli, A.M.; Evangelisti, C.; Chiarini, F.; Grimaldi, C.; McCubrey, J.A. The Emerging Role of the Phosphatidylinositol 3-Kinase/ Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cell Biology. Cancer, 2010, 2(3), 1576-1596.
34. Myers, M.P.; Pass, I.; Batty, I.H.; Van der Kaay, J.; Stolarov, J.P.; Hemmings, B.A.; Wigler, M.H.; Downes, C.P.; Tonks, N.K. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. USA., 1998, 95(23), 13513-13518.
35. Sun, X.; Huang, J.; Homma, T.; Kita, D.; Klocker, H.; Schafer, G.; Boyle, P.; Ohgaki, H. Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res., 2009, 29(5), 1739-1743.
36. Porkka, K.P.; Visakorpi, T. Molecular mechanisms of prostate cancer. Eur. Urol., 2004, 45(6), 683-691.
37. Roychowdhury, S.; Chinnaiyan, A.M. Advancing precision medicine for prostate cancer through genomics. Int. J. Clin. Oncol., 2013, 31(15), 1866-1873.
38. Grasso, C.S.; Wu, Y.M.; Robinson, D.R.; Cao, X.; Dhanasekaran, S.M.; Khan, A.P.; Quist, M.J.; Jing, X.; Lonigro, R.J.; Brenner, J.C.; Asangani, I.A.; Ateeq, B.; Chun, S.Y.; Siddiqui, J.; Sam, L.; Anstett, M.; Mehra, R.; Prensner, J.R.; Palanisamy, N.; Ryslik, G.A.; Vandin, F.; Raphael, B.J.; Kunju, L.P.; Rhodes, D.R.; Pienta, K.J.; Chinnaiyan, A.M.; Tomlins, S.A. The mutational landscape of lethal castration-resistant prostate cancer. Nature, 2012, 487(7406), 239-243.
39. Berger, M.F.; Lawrence, M.S.; Demichelis, F.; Drier, Y.; Cibulskis, K.; Sivachenko, A.Y.; Sboner, A.; Esgueva, R.; Pflueger, D.; Sougnez, C.; Onofrio, R.; Carter, S.L.; Park, K.; Habegger, L.; Ambrogio, L.; Fennell, T.; Parkin, M.; Saksena, G.; Voet, D.; Ramos, A.H.; Pugh, T.J.; Wilkinson, J.; Fisher, S.; Winckler, W.; Mahan, S.; Ardlie, K.; Baldwin, J.; Simons, J.W.; Kitabayashi, N.; MacDonald, T.Y.; Kantoff, P.W.; Chin, L.; Gabriel, S.B.; Gerstein, M.B.; Golub, T.R.; Meyerson, M.; Tewari, A.; Lander, E.S.; Getz, G.; Rubin, M.A.; Garraway, L.A. The genomic complexity of primary human prostate cancer. Nature, 2011, 470(7333), 214-220.
40. Majumder, P.K.; Sellers, W.R. Akt-regulated pathways in prostate cancer. Oncogene, 2005, 24(50), 7465-7474.
41. Li, J.; Yen, C.; Liaw, D.; Podsypanina, K.; Bose, S.; Wang, S.I.; Puc, J.; Miliaresis, C.; Rodgers, L.; McCombie, R.; Bigner, S.H.; Giovanella, B.C.; Ittmann, M.; Tycko, B.; Hibshoosh, H.; Wigler, M.H.; Parsons, R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science, 1997, 275(5308), 1943-1947.
42. Suzuki, H.; Freije, D.; Nusskern, D.R.; Okami, K.; Cairns, P.; Sidransky, D.; Isaacs, W.B.; Bova, G.S. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res., 1998, 58(2), 204-209.
43. de Muga, S.; Hernandez, S.; Agell, L.; Salido, M.; Juanpere, N.; Lorenzo, M.; Lorente, J.A.; Serrano, S.; Lloreta, J. Molecular alterations of EGFR and PTEN in prostate cancer: association with high-grade and advanced-stage carcinomas. Mod. Pathol., 2010, 23(5), 703-712.
44. Shayesteh, L.; Lu, Y.; Kuo, W.L.; Baldocchi, R.; Godfrey, T.; Collins, C.; Pinkel, D.; Powell, B.; Mills, G.B.; Gray, J.W. PIK3CA is implicated as an oncogene in ovarian cancer. Nat. Genet., 1999, 21(1), 99-102.
45. Beltran, H.; Rickman, D.S.; Park, K.; Chae, S.S.; Sboner, A.; MacDonald, T.Y.; Wang, Y.; Sheikh, K.L.; Terry, S.; Tagawa, S.T.; Dhir, R.; Nelson, J.B.; de la Taille, A.; Allory, Y.; Gerstein, M.B.; Perner, S.; Pienta, K.J.; Chinnaiyan, A.M.; Wang, Y.; Collins, C.C.; Gleave, M.E.; Demichelis, F.; Nanus, D.M.; Rubin, M.A. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov., 2011, 1(6), 487-495.
46. Agell, L.; Hernandez, S.; Salido, M.; de Muga, S.; Juanpere, N.; Arumi-Uria, M.; Menendez, S.; Lorenzo, M.; Lorente, J.A.; Serrano, S.; Lloreta, J. PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events. Mod. Pathol., 2011, 24(3), 443-452.
47. Sarker, D.; Reid, A.H.; Yap, T.A.; de Bono, J.S. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin. Cancer Res., 2009, 15(15), 4799-4805.
48. Shukla, S.; Maclennan, G.T.; Hartman, D.J.; Fu, P.; Resnick, M.I.; Gupta, S. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int. J. Cancer, 2007, 121(7), 1424-1432.
49. Renner, O.; Fominaya, J.; Alonso, S.; Blanco-Aparicio, C.; Leal, J.F.; Carnero, A. Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate. Carcinogenesis, 2007, 28(7), 1418-1425.
50. Furic, L.; Rong, L.; Larsson, O.; Koumakpayi, I.H.; Yoshida, K.; Brueschke, A.; Petroulakis, E.; Robichaud, N.; Pollak, M.; Gaboury, L.A.; Pandolfi, P.P.; Saad, F.; Sonenberg, N. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc. Natl. Acad. Sci. USA., 2010, 107(32), 14134-14139.
51. Hill, R.; Wu, H. PTEN, stem cells, and cancer stem cells. J. Biol. Chem., 2009, 284(18), 11755-11759.
52. Singh, A.; Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene, 2010, 29(34), 4741-4751.
53. Dunn, S.E.; Torres, J.V.; Oh, J.S.; Cykert, D.M.; Barrett, J.C. Upregulation of urokinase-type plasminogen activator by insulin-like growth factor-I depends upon phosphatidylinositol-3 kinase and mitogen-activated protein kinase kinase. Cancer Res., 2001, 61(4), 1367-1374.
54. Wilson, T.J.; Singh, R.K. Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases. Biochim. Biophys. Acta, 2008, 1785(2), 85-95.
55. Chen, J.S.; Wang, Q.; Fu, X.H.; Huang, X.H.; Chen, X.L.; Cao, L.Q.; Chen, L.Z.; Tan, H.X.; Li, W.; Bi, J.; Zhang, L.J. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol. Res., 2009, 39(2), 177-186.
56. Mulholland, D.J.; Kobayashi, N.; Ruscetti, M.; Zhi, A.; Tran, L.M.; Huang, J.; Gleave, M.; Wu, H. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res., 2012, 72(7), 1878-1889.
57. Lang, S.H.; Frame, F.M.; Collins, A.T. Prostate cancer stem cells. J. Pathol., 2009, 217(2), 299-306.
58. Wang, X.; Kruithof-de Julio, M.; Economides, K.D.; Walker, D.; Yu, H.; Halili, M.V.; Hu, Y.P.; Price, S.M.; Abate-Shen, C.; Shen, M.M. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature, 2009, 461(7263), 495-500.
59. Wang, S.; Garcia, A.J.; Wu, M.; Lawson, D.A.; Witte, O.N.; Wu, H. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc. Natl. Acad. Sci. USA., 2006, 103(5), 1480-1485.
60. Mulholland, D.J.; Xin, L.; Morim, A.; Lawson, D.; Witte, O.; Wu, H. Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res., 2009, 69(22), 8555-8562.
61. Lawson, D.A.; Zong, Y.; Memarzadeh, S.; Xin, L.; Huang, J.; Witte, O.N. Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc. Natl. Acad. Sci. USA., 2010, 107(6), 2610-2615.
62. Dubrovska, A.; Kim, S.; Salamone, R.J.; Walker, J.R.; Maira, S.M.; Garcia-Echeverria, C.; Schultz, P.G.; Reddy, V.A. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc. Natl. Acad. Sci. USA., 2009, 106(1), 268-273.
63. West, K.A.; Castillo, S.S.; Dennis, P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Updat., 2002, 5(6), 234-248.
64. Grunwald, V.; DeGraffenried, L.; Russel, D.; Friedrichs, W.E.; Ray, R.B.; Hidalgo, M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res., 2002, 62(21), 6141-6145.
65. Dubrovska, A.; Elliott, J.; Salamone, R.J.; Kim, S.; Aimone, L.J.; Walker, J.R.; Watson, J.; Sauveur-Michel, M.; Garcia-Echeverria, C.; Cho, C.Y.; Reddy, V.A.; Schultz, P.G. Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. Clin. Cancer Res., 2010, 16(23), 5692-5702.
66. Aggarwal, R.; Ryan, C.J. Castration-resistant prostate cancer: targeted therapies and individualized treatment. Oncologist, 2011, 16(3), 264-275.
67. Shen, M.M.; Abate-Shen, C. Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res., 2007, 67(14), 6535-6538.
68. Wang, S.; Gao, J.; Lei, Q.; Rozengurt, N.; Pritchard, C.; Jiao, J.; Thomas, G.V.; Li, G.; Roy-Burman, P.; Nelson, P.S.; Liu, X.; Wu, H. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell., 2003, 4(3), 209-221.
69. Pfeil, K.; Eder, I.E.; Putz, T.; Ramoner, R.; Culig, Z.; Ueberall, F.; Bartsch, G.; Klocker, H. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate, 2004, 58(3), 259-268.
70. van der Heijden, M.S.; Bernards, R. Inhibition of the PI3K pathway: hope we can believe in? Clin. Cancer Res., 2010, 16(12), 3094-3099.
71. Mazzoletti, M.; Bortolin, F.; Brunelli, L.; Pastorelli, R.; Di Giandomenico, S.; Erba, E.; Ubezio, P.; Broggini, M. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res., 2011, 71(13), 4573-4584.
72. Hassan, B.; Akcakanat, A.; Holder, A.M.; Meric-Bernstam, F. Targeting the PI3-Kinase/Akt/mTOR Signaling Pathway. Surg. Oncol. Clin. North Am., 2013, 22(4), 641-664.
73. Feldman, M.E.; Apsel, B.; Uotila, A.; Loewith, R.; Knight, Z.A.; Ruggero, D.; Shokat, K.M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol., 2009, 7(2), e38.
74. Feldman, M.E.; Apsel, B.; Uotila, A.; Loewith, R.; Knight, Z.A.; Ruggero, D.; Shokat, K.M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol., 2009, 7(2), e38.
75. McMahon, L.P.; Choi, K.M.; Lin, T.A.; Abraham, R.T.; Lawrence, J.C., Jr. The rapamycin-binding domain governs substrate selectivity by the mammalian target of rapamycin. Mol. Cell. Biol., 2002, 22(21), 7428-7438.
76. Wang, X.; Beugnet, A.; Murakami, M.; Yamanaka, S.; Proud, C.G. Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4Ebinding proteins. Mol. Cell. Biol., 2005, 25(7), 2558-2572.
77. Fang, J.; Ding, M.; Yang, L.; Liu, L.Z.; Jiang, B.H. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell. Signal., 2007, 19(12), 2487-2497.
78. Gottschalk, A.R.; Doan, A.; Nakamura, J.L.; Stokoe, D.; Haas-Kogan, D.A. Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism. Int. J. Rad. Oncol. Biol. Phys., 2005, 63(4), 1221-1227.
79. Baldo, P.; Cecco, S.; Giacomin, E.; Lazzarini, R.; Ros, B.; Marastoni, S. mTOR pathway and mTOR inhibitors as agents for cancer therapy. Curr. Cancer Drug Targets, 2008, 8(8), 647-665.
80. Garlich, J.R.; De, P.; Dey, N.; Su, J.D.; Peng, X.; Miller, A.; Murali, R.; Lu, Y.; Mills, G.B.; Kundra, V.; Shu, H.K.; Peng, Q.; Durden, D.L. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res., 2008, 68(1), 206-215.
81. Mahadevan, D.; Chiorean, E.G.; Harris, W.B.; Von Hoff, D.D.; Stejskal-Barnett, A.; Qi, W.; Anthony, S.P.; Younger, A.E.; Rensvold, D.M.; Cordova, F.; Shelton, C.F.; Becker, M.D.; Garlich, J.R.; Durden, D.L.; Ramanathan, R.K. Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur. J. Cancer, 2012, 48(18), 3319-3327.
82. Haddad, A.Q.; Fleshner, N.; Nelson, C.; Saour, B.; Musquera, M.; Venkateswaran, V.; Klotz, L. Antiproliferative mechanisms of the flavonoids 2,2'-dihydroxychalcone and fisetin in human prostate cancer cells. Nutr. Cancer, 2010, 62(5), 668-681.
83. Khan, N.; Asim, M.; Afaq, F.; Abu Zaid, M.; Mukhtar, H. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res., 2008, 68(20), 8555-8563.
84. Suh, Y.; Afaq, F.; Khan, N.; Johnson, J.J.; Khusro, F.H.; Mukhtar, H. Fisetin induces autophagic cell death through suppression of mTOR signaling pathway in prostate cancer cells. Carcinogenesis, 2010, 31(8), 1424-1433.
85. Adhami, V.M.; Syed, D.N.; Khan, N.; Mukhtar, H. Dietary flavonoid fisetin: A novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem. Pharmacol., 2012, 84(10), 1277-1281.
86. Hu, L.; Zaloudek, C.; Mills, G.B.; Gray, J.; Jaffe, R.B. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin. Cancer Res., 2000, 6(3), 880-886.
87. Gupta, A.K.; Cerniglia, G.J.; Mick, R.; Ahmed, M.S.; Bakanauskas, V.J.; Muschel, R.J.; McKenna, W.G. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int. J. Rad. Oncol. Biol. Phys., 2003, 56(3), 846-853.